nach oben

Die Innere Medizin

Erschienen in:

01.05.2008 | Schwerpunkt: Hormontherapie

Wachstumshormontherapie beim Erwachsenen

Versuch einer Bilanz nach einer Dekade

verfasst von: Dr. M. Faust, C.J. Strasburger

Erschienen in: Die Innere Medizin | Ausgabe 5/2008

Einloggen, um Zugang zu erhalten

Zusammenfassung

Patienten mit adultem Wachstumshormonmangel können offenbar unabhängig vom Ausfall und von der Substitution weiterer hypophysärer Achsen ein Krankheitsbild mit zentral betonter Adipositas, Dyslipidämie, verminderter Knochendichte und erhöhter Frakturrate sowie psychosozialen Einschränkungen entwickeln. Dabei ist das Ausmaß dieser Veränderungen starken interindividuellen Schwankungen unterlegen. Retrospektive Analysen weisen auf eine möglicherweise erhöhte kardiovaskuläre Morbidität und Mortalität dieses Patientenkollektivs hin, welche durch die proatherogenen Veränderungen (zentrale Adipositas, Dyslipidämie) bedingt sein könnten. Die Therapie mit rekombinantem Wachstumshormon führt in kontrollierten Studien neben einer deutlichen Verbesserung der Lebensqualität zur Verbesserung der Körperzusammensetzung und des Lipidprofils sowie zur Erhöhung der Knochendichte. Ob sich diese Verbesserungen auch in der Reduktion von Endpunkten (Senkung der Frakturraten, Senkung der kardiovaskulären Morbidität und Mortalität) auszahlt, ist durch kontrollierte Studien bislang nicht belegt. Bei Verwendung niedriger Dosen, die anhand des IGF-1-Spiegels titriert werden, scheint die Wachstumshormonsubstitution eine sichere, gut verträgliche Therapie zu sein.

(2001) Critical evaluation of the safety of recombinant human growth hormone administration: statement from the Growth Hormone Research Society. J Clin Endocrinol Metab 86: 1868–1870

Ahmad AM, Hopkins MT, Thomas J et al. (2001) Body composition and quality of life in adults with growth hormone deficiency; effects of low-dose growth hormone replacement. Clin Endocrinol (Oxf) 54: 709–717

Alberti KG, Zimmet P, Shaw J (2005) The metabolic syndrome – a new worldwide definition. Lancet 366: 1059–1062PubMedCrossRef

Almqvist O, Thorén M, Sääf M, Eriksson O(1986) Effects of growth hormone substitution on mental performance in adults with growth hormone deficiency: a pilot study. Psychoneuroendocrinology 11: 347–352PubMedCrossRef

Al-Shoumer KA, Page B, Thomas E et al. (1996) Effects of four years‘ treatment with biosynthetic human growth hormone (GH) on body composition in GH-deficient hypopituitary adults. Eur J Endocrinol 135: 559–567PubMed

Amato G, Carella C, Fazio S et al. (1993) Body composition, bone metabolism, and heart structure and function in growth hormone (GH)-deficient adults before and after GH replacement therapy at low doses. J Clin Endocrinol Metab 77: 1671–1676PubMedCrossRef

Amato G, Izzo G, La Montagna G, Bellastella A (1996) Low dose recombinant human growth hormone normalizes bone metabolism and cortical bone density and improves trabecular bone density in growth hormone deficient adults without causing adverse effects. Clin Endocrinol (Oxf) 45: 27–32

Arwert LI, Deijen JB, Drent ML (2005) Effects of growth hormone deficiency and growth hormone treatment on quality of life in growth hormone-deficient adults. Front Horm Res 33: 196–208PubMed

Attanasio AF, Bates PC, Ho KK et al.; Hypoptiuitary Control and Complications Study International Advisory Board (2002) Human growth hormone replacement in adult hypopituitary patients: long-term effects on body composition and lipid status–3-year results from the HypoCCS Database. J Clin Endocrinol Metab 87: 1600–1606PubMedCrossRef

10.

Attanasio AF, Lamberts SW, Matranga AM et al. (1997) Adult growth hormone (GH)-deficient patients demonstrate heterogeneity between childhood onset and adult onset before and during human GH treatment. Adult Growth Hormone Deficiency Study Group. J Clin Endocrinol Metab 82: 82–88PubMedCrossRef

11.

Bates AS, Van’t Hoff W, Jones PJ, Clayton RN (1996) The effect of hypopituitarism on life expectancy. J Clin Endocrinol Metab 81: 1169–1172PubMedCrossRef

12.

Baum HB, Biller BM, Finkelstein JS et al. (1996) Effects of physiologic growth hormone therapy on bone density and body composition in patients with adult-onset growth hormone deficiency. A randomized, placebo-controlled trial. Ann Intern Med 125: 883–890PubMed

13.

Baum HB, Katznelson L, Sherman JC et al. (1998) Effects of physiological growth hormone (GH) therapy on cognition and quality of life in patients with adult-onset GH deficiency. J Clin Endocrinol Metab 83: 3184–3189PubMedCrossRef

14.

Bell W, Davies JS, Evans WD et al. (2004) Somatic characteristics and cardiovascular risk factors in growth hormone deficiency: a randomized, double-blind, placebo-controlled study of the effect of treatment with recombinant human growth hormone. Am J Hum Biol 16: 533–543PubMedCrossRef

15.

Bengtsson BA, Edén S, Lönn L et al. (1993) Treatment of adults with growth hormone (GH) deficiency with recombinant human GH. J Clin Endocrinol Metab 76: 309–317PubMedCrossRef

16.

Beshyah SA, Freemantle C, Shahi M et al. (1995) Replacement treatment with biosynthetic human growth hormone in growth hormone-deficient hypopituitary adults. Clin Endocrinol (Oxf) 42: 73–84

17.

Beshyah SA, Freemantle C, Thomas E et al. (1995) Abnormal body composition and reduced bone mass in growth hormone deficient hypopituitary adults. Clin Endocrinol (Oxf) 42: 179–189

18.

Beshyah SA, Henderson A, Niththyananthan R et al. (1995) The effects of short and long-term growth hormone replacement therapy in hypopituitary adults on lipid metabolism and carbohydrate tolerance. J Clin Endocrinol Metab 80: 356–363PubMedCrossRef

19.

Biller BM, Sesmilo G, Baum HB et al. (2000) Withdrawal of long-term physiological growth hormone (GH) administration: differential effects on bone density and body composition in men with adult-onset GH deficiency. J Clin Endocrinol Metab 85: 970–976PubMedCrossRef

20.

Bing-You RG, Denis MC, Rosen CJ (1993) Low bone mineral density in adults with previous hypothalamic-pituitary tumors: correlations with serum growth hormone responses to GH-releasing hormone, insulin-like growth factor I, and IGF binding protein 3. Calcif Tissue Int 52: 183–187PubMedCrossRef

21.

Binnerts A, Swart GR, Wilson JH et al. (1992) The effect of growth hormone administration in growth hormone deficient adults on bone, protein, carbohydrate and lipid homeostasis, as well as on body composition. Clin Endocrinol (Oxf) 37: 79–87

22.

Bjork S, Jönsson B, Westphal O, Levin JE (1989) Quality of life of adults with growth hormone deficiency: a controlled study. Acta Paediatr Scand Suppl 356: 55–59PubMedCrossRef

23.

Blethen SL, Allen DB, Graves D et al. (1996) Safety of recombinant deoxyribonucleic acid-derived growth hormone: The National Cooperative Growth Study experience. J Clin Endocrinol Metab 81: 1704–1710PubMedCrossRef

24.

Böger RH, Skamira C, Bode-Böger SM et al. (1996) Nitric oxide may mediate the hemodynamic effects of recombinant growth hormone in patients with acquired growth hormone deficiency. A double-blind, placebo-controlled study. J Clin Invest 98: 2706–2713PubMedCrossRef

25.

Bramnert M, Segerlantz M, Laurila E et al. (2003) Growth hormone replacement therapy induces insulin resistance by activating the glucose-fatty acid cycle. J Clin Endocrinol Metab 88: 1455–1463PubMedCrossRef

26.

Buchanan CR, Preece MA, Milner RD (1991) Mortality, neoplasia, and Creutzfeldt-Jakob disease in patients treated with human pituitary growth hormone in the United Kingdom. BMJ 302: 824–828PubMed

27.

Burman P, Broman JE, Hetta J et al. (1995) Quality of life in adults with growth hormone (GH) deficiency: response to treatment with recombinant human GH in a placebo-controlled 21-month trial. J Clin Endocrinol Metab 80: 3585–3590PubMedCrossRef

28.

Carroll PV, Christ ER, Bengtsson BA et al. (1998) Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review. Growth Hormone Research Society Scientific Committee. J Clin Endocrinol Metab 83: 382–395PubMedCrossRef

29.

Carroll PV, Drake WM, Maher KT et al. (2004) Comparison of continuation or cessation of growth hormone (GH) therapy on body composition and metabolic status in adolescents with severe GH deficiency at completion of linear growth. J Clin Endocrinol Metab 89: 3890–3895PubMedCrossRef

30.

Carroll PV, Littlewood R, Weissberger AJ et al. (1997) The effects of two doses of replacement growth hormone on the biochemical, body composition and psychological profiles of growth hormone-deficient adults. Eur J Endocrinol 137: 146–153PubMedCrossRef

31.

Chihara K, Koledova E, Shimatsu A et al. (2004) Adult GH deficiency in Japanese patients: effects of GH treatment in a randomised, placebo-controlled trial. Eur J Endocrinol 151: 343–350PubMedCrossRef

32.

Chipman JJ, Attanasio AF, Birkett MA et al. (1997) The safety profile of GH replacement therapy in adults. Clin Endocrinol (Oxf) 46: 473–481

33.

Chong PK, Jung RT, Scrimgeour CM et al. (1994) Energy expenditure and body composition in growth hormone deficient adults on exogenous growth hormone. Clin Endocrinol (Oxf) 40: 103–110

34.

Chrisoulidou A, Beshyah SA, Rutherford O et al. (2000) Effects of 7 years of growth hormone replacement therapy in hypopituitary adults. J Clin Endocrinol Metab 85: 3762–3769PubMedCrossRef

35.

Christ ER, Cummings MH, Albany E et al. (1999) Effects of growth hormone (GH) replacement therapy on very low density lipoprotein apolipoprotein B100 kinetics in patients with adult GH deficiency: a stable isotope study. J Clin Endocrinol Metab 84: 307–316PubMedCrossRef

36.

Christ ER, Cummings MH, Lumb PJ et al. (1999) Growth hormone (GH) replacement therapy reduces serum sialic acid concentrations in adults with GH-deficiency: a double-blind placebo-controlled study. Clin Endocrinol (Oxf) 51: 173–179

37.

Christ ER, Cummings MH, Westwood NB et al. (1997) The importance of growth hormone in the regulation of erythropoiesis, red cell mass, and plasma volume in adults with growth hormone deficiency. J Clin Endocrinol Metab 82: 2985–2990PubMedCrossRef

38.

Cohn L, Feller AG, Draper MW et al. (1993) Carpal tunnel syndrome and gynaecomastia during growth hormone treatment of elderly men with low circulating IGF-I concentrations. Clin Endocrinol (Oxf) 39: 417–425

39.

Colao A, Di Somma C, Cuocolo A et al. (2001) Improved cardiovascular risk factors and cardiac performance after 12 months of growth hormone (GH) replacement in young adult patients with GH deficiency. J Clin Endocrinol Metab 86: 1874–1881PubMedCrossRef

40.

Colao A, Di Somma C, Pivonello R et al. (1999) Bone loss is correlated to the severity of growth hormone deficiency in adult patients with hypopituitarism. J Clin Endocrinol Metab 84: 1919–1924PubMedCrossRef

41.

Cuneo RC, Judd S, Wallace JD et al. (1998) The Australian Multicenter Trial of Growth Hormone (GH) Treatment in GH-Deficient Adults. J Clin Endocrinol Metab 83: 107–116PubMedCrossRef

42.

Cuneo RC, Salomon F, Watts GF et al. (1993) Growth hormone treatment improves serum lipids and lipoproteins in adults with growth hormone deficiency. Metabolism 42: 1519–1523PubMedCrossRef

43.

Cuneo RC, Salomon F, Wiles CM et al. (1991) Growth hormone treatment in growth hormone-deficient adults. I. Effects on muscle mass and strength. J Appl Physiol 70: 688–694PubMed

44.

Dattani M, Preece M (2004) Growth hormone deficiency and related disorders: insights into causation, diagnosis, and treatment. Lancet 363: 1977–1987PubMedCrossRef

45.

Davidson P, Milne R, Chase D, Cooper C (2004) Growth hormone replacement in adults and bone mineral density: a systematic review and meta-analysis. Clin Endocrinol (Oxf) 60: 92–98

46.

De Boer H, Blok GJ, van Lingen A et al. (1994) Consequences of childhood-onset growth hormone deficiency for adult bone mass. J Bone Miner Res 9: 1319–1326CrossRef

47.

De Boer H, Blok GJ, Voerman HJ et al. (1992) Body composition in adult growth hormone-deficient men, assessed by anthropometry and bioimpedance analysis. J Clin Endocrinol Metab 75: 833–837CrossRef

48.

Degerblad M, Almkvist O, Grunditz R et al. (1990) Physical and psychological capabilities during substitution therapy with recombinant growth hormone in adults with growth hormone deficiency. Acta Endocrinol (Copenh) 123: 185–193

49.

Degerblad M, Bengtsson BA, Bramnert M et al. (1995) Reduced bone mineral density in adults with growth hormone (GH) deficiency: increased bone turnover during 12 months of GH substitution therapy. Eur J Endocrinol 133: 180–188PubMed

50.

Deijen JB, de Boer H, Blok GJ et al. (1996) Cognitive impairments and mood disturbances in growth hormone deficient men. Psychoneuroendocrinology 21: 313–322PubMedCrossRef

51.

Deijen JB, de Boer H, van der Veen EA (1998) Cognitive changes during growth hormone replacement in adult men. Psychoneuroendocrinology 23: 45–55PubMedCrossRef

52.

Despres JP, Lemieux I, Prud’homme D (2001) Treatment of obesity: need to focus on high risk abdominally obese patients. BMJ 322: 716–720PubMedCrossRef

53.

Drake WM, Rodríguez-Arnao J, Weaver JU et al. (2001) The influence of gender on the short and long-term effects of growth hormone replacement on bone metabolism and bone mineral density in hypopituitary adults: a 5-year study. Clin Endocrinol (Oxf) 54: 525–532

54.

Edén S, Wiklund O, Oscarsson J et al. (1993) Growth hormone treatment of growth hormone-deficient adults results in a marked increase in Lp(a) and HDL cholesterol concentrations. Arterioscler Thromb 13: 296–301PubMed

55.

Ezzat S, Fear S, Gaillard RC et al. (2002) Gender-specific responses of lean body composition and non-gender-specific cardiac function improvement after GH replacement in GH-deficient adults. J Clin Endocrinol Metab 87: 2725–2733PubMedCrossRef

56.

Fernholm R, Bramnert M, Hägg E et al. (2000) Growth hormone replacement therapy improves body composition and increases bone metabolism in elderly patients with pituitary disease. J Clin Endocrinol Metab 85: 4104–4112PubMedCrossRef

57.

Finkenstedt G, Gasser RW, Höfle G et al. (1997) Effects of growth hormone (GH) replacement on bone metabolism and mineral density in adult onset of GH deficiency: results of a double-blind placebo-controlled study with open follow-up. Eur J Endocrinol 136: 282–289PubMed

58.

Fowelin J, Attvall S, Lager I, Bengtsson BA (1993) Effects of treatment with recombinant human growth hormone on insulin sensitivity and glucose metabolism in adults with growth hormone deficiency. Metabolism 42: 1443–1447PubMedCrossRef

59.

Garry P, Collins P, Devlin JG (1996) An open 36-month study of lipid changes with growth hormone in adults: lipid changes following replacement of growth hormone in adult acquired growth hormone deficiency. Eur J Endocrinol 134: 61–66PubMed

60.

Gibney J, Wallace JD, Spinks T et al. (1999) The effects of 10 years of recombinant human growth hormone (GH) in adult GH-deficient patients. J Clin Endocrinol Metab 84: 2596–2602PubMedCrossRef

61.

Giusti M, Meineri I, Malagamba D et al. (1998) Impact of recombinant human growth hormone treatment on psychological profiles in hypopituitary patients with adult-onset growth hormone deficiency. Eur J Clin Invest 28: 13–19PubMedCrossRef

62.

Gómez JM, Gómez N, Fiter J, Soler J (2000) Effects of long-term treatment with GH in the bone mineral density of adults with hypopituitarism and GH deficiency and after discontinuation of GH replacement. Horm Metab Res 32: 66–70PubMed

63.

Gotherstrom G, Svensson J, Koranyi J et al. (2001) A prospective study of 5 years of GH replacement therapy in GH-deficient adults: sustained effects on body composition, bone mass, and metabolic indices. J Clin Endocrinol Metab 86: 4657–4665PubMedCrossRef

64.

Hansen R, Koller EA, Malozowski S (2000) Full remission of growth hormone (GH)-induced retinopathy after GH treatment discontinuation: long-term follow-up. J Clin Endocrinol Metab 85: 2627PubMedCrossRef

65.

Hansen TB, Brixen K, Vahl N et al. (1996) Effects of 12 months of growth hormone (GH) treatment on calciotropic hormones, calcium homeostasis, and bone metabolism in adults with acquired GH deficiency: a double blind, randomized, placebo-controlled study. J Clin Endocrinol Metab 81: 3352–3359PubMedCrossRef

66.

Hernberg-Stahl E, Luger A, Abs R et al.; KIMS International Board; KIMS Study Group. Pharmacia International Metabolic Database (2001) Healthcare consumption decreases in parallel with improvements in quality of life during GH replacement in hypopituitary adults with GH deficiency. J Clin Endocrinol Metab 86: 5277–5281PubMedCrossRef

67.

Hoffman AR, Kuntze JE, Baptista J et al. (2004) Growth hormone (GH) replacement therapy in adult-onset gh deficiency: effects on body composition in men and women in a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab 89: 2048–2056PubMedCrossRef

68.

Hoffman DM, O’Sullivan AJ, Freund J, Ho KK (1995) Adults with growth hormone deficiency have abnormal body composition but normal energy metabolism. J Clin Endocrinol Metab 80: 72–77PubMedCrossRef

69.

Holmes SJ, Economou G, Whitehouse RW et al. (1994) Reduced bone mineral density in patients with adult onset growth hormone deficiency. J Clin Endocrinol Metab 78: 669–674PubMedCrossRef

70.

Holmes SJ, Whitehouse RW, Swindell R et al. (1995) Effect of growth hormone replacement on bone mass in adults with adult onset growth hormone deficiency. Clin Endocrinol (Oxf) 42: 627–633

71.

Hwu CM, Kwok CF, Lai TY et al. (1997) Growth hormone (GH) replacement reduces total body fat and normalizes insulin sensitivity in GH-deficient adults: a report of one-year clinical experience. J Clin Endocrinol Metab 82: 3285–3292PubMedCrossRef

72.

Hyer SL, Rodin DA, Tobias JH et al. (1992) Growth hormone deficiency during puberty reduces adult bone mineral density. Arch Dis Child 67: 1472–1474PubMed

73.

Janssen YJ, Doornbos J, Roelfsema F (1999) Changes in muscle volume, strength, and bioenergetics during recombinant human growth hormone (GH) therapy in adults with GH deficiency. J Clin Endocrinol Metab 84: 279–284PubMedCrossRef

74.

Johannsson G, Bengtsson BA, Andersson B et al. (1996) Long-term cardiovascular effects of growth hormone treatment in GH-deficient adults. Preliminary data in a small group of patients. Clin Endocrinol (Oxf) 45: 305–314

75.

Johannsson G, Bjarnason R, Bramnert M et al. (1996) The individual responsiveness to growth hormone (GH) treatment in GH-deficient adults is dependent on the level of GH-binding protein, body mass index, age, and gender. J Clin Endocrinol Metab 81: 1575–1581PubMedCrossRef

76.

Johannsson G, Grimby G, Sunnerhagen KS et al. (1997) Two years of growth hormone (GH) treatment increase isometric and isokinetic muscle strength in GH-deficient adults. J Clin Endocrinol Metab 82: 2877–2884PubMedCrossRef

77.

Johannsson G, Mårin P, Lönn L et al. (1997) Growth hormone treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism, and reduces diastolic blood pressure. J Clin Endocrinol Metab 82: 727–734PubMedCrossRef

78.

Johannsson G, Oscarsson J, Rosén T et al. (1995) Effects of 1 year of growth hormone therapy on serum lipoprotein levels in growth hormone-deficient adults. Influence of gender and Apo(a) and ApoE phenotypes. Arterioscler Thromb Vasc Biol 15: 2142–2150PubMed

79.

Johannsson G, Rosén T, Bosaeus I et al. (1996) Two years of growth hormone (GH) treatment increases bone mineral content and density in hypopituitary patients with adult-onset GH deficiency. J Clin Endocrinol Metab 81: 2865–2873PubMedCrossRef

80.

Johannsson G, Rosén T, Lönn L, Bengtsson BA et al. (1994) Effects of recombinant human growth hormone on adipose tissue in adults with growth hormone deficiency. Acta Paediatr Suppl 406: 60–63PubMedCrossRef

81.

Johansen JS, Pedersen SA, Jørgensen JO et al. (1990) Effects of growth hormone (GH) on plasma bone Gla protein in GH-deficient adults. J Clin Endocrinol Metab 70: 916–919PubMed

82.

Johansson JO, Fowelin J, Landin K et al. (1995) Growth hormone-deficient adults are insulin-resistant. Metabolism 44: 1126–1129PubMedCrossRef

83.

Jorgensen JO, Pedersen SA, Ingerslev J et al. (1990) Growth hormone (GH) therapy in GH-deficient patients, the plasma factor VIII-von Willebrand factor complex, and capillary fragility. A double-blind, placebo-controlled crossover study. Scand J Clin Lab Invest 50: 417–420PubMedCrossRef

84.

Jorgensen JO, Pedersen SA, Thuesen L et al. (1989) Beneficial effects of growth hormone treatment in GH-deficient adults. Lancet 1: 1221–1225PubMedCrossRef

85.

Juul A et, Pedersen SA, Sørensen S al. (1994) Growth hormone (GH) treatment increases serum insulin-like growth factor binding protein-3, bone isoenzyme alkaline phosphatase and forearm bone mineral content in young adults with GH deficiency of childhood onset. Eur J Endocrinol 131: 41–49PubMed

86.

Kann P, Piepkorn B, Schehler B et al. (1996) Growth hormone substitution in growth hormone-deficient adults: effects on collagen type I synthesis and skin thickness. Exp Clin Endocrinol Diabetes 104: 327–333PubMedCrossRef

87.

Kann P, Piepkorn B, Schehler B et al. (1998) Effect of long-term treatment with GH on bone metabolism, bone mineral density and bone elasticity in GH-deficient adults. Clin Endocrinol (Oxf) 48: 561–568

88.

Kaufman JM, Taelman P, Vermeulen A, Vandeweghe M (1992) Bone mineral status in growth hormone-deficient males with isolated and multiple pituitary deficiencies of childhood onset. J Clin Endocrinol Metab 74: 118–123PubMedCrossRef

89.

Koller EA, Green L, Gertner JM et al. (1998) Retinal changes mimicking diabetic retinopathy in two nondiabetic, growth hormone-treated patients. J Clin Endocrinol Metab 83: 2380–2383PubMedCrossRef

90.

Koltowska-Haggstrom M, Hennessy S, Mattsson AF et al. (2005) Quality of life assessment of growth hormone deficiency in adults (QoL-AGHDA): Comparison of normative reference data for the general population of England and Wales with results for adult hypopituitary patients with growth hormone deficiency. Horm Res 64: 46–54PubMedCrossRef

91.

Kotzmann H, Riedl M, Bernecker P et al. (1998) Effect of long-term growth-hormone substitution therapy on bone mineral density and parameters of bone metabolism in adult patients with growth hormone deficiency. Calcif Tissue Int 62: 40–46PubMedCrossRef

92.

Kousta E, Chrisoulidou A, Lawrence NJ et al. (2000) The effects of growth hormone replacement therapy on overnight metabolic fuels in hypopituitary patients. Clin Endocrinol (Oxf) 52: 17–24

93.

Laron Z, Wang XL, Klinger B et al. (1997) Growth hormone increases and insulin-like growth factor-I decreases circulating lipoprotein(a). Eur J Endocrinol 136: 377–381PubMed

94.

Leese GP, Wallymahmed M, VanHeyningen C et al. (1998) HDL-cholesterol reductions associated with adult growth hormone replacement. Clin Endocrinol (Oxf) 49: 673–677

95.

Lynch S, Merson S, Beshyah SA et al. (1994) Psychiatric morbidity in adults with hypopituitarism. J R Soc Med 87: 445–447PubMed

96.

Maison P, Chanson P (2003) Cardiac effects of growth hormone in adults with growth hormone deficiency: a meta-analysis. Circulation 108: 2648–2652PubMedCrossRef

97.

Maison P, Griffin S, Nicoue-Beglah M et al. (2004) Impact of growth hormone (GH) treatment on cardiovascular risk factors in GH-deficient adults: a metaanalysis of blinded, randomized, placebo-controlled trials. J Clin Endocrinol Metab 89: 2192–2199PubMedCrossRef

98.

McGauley GA (1989) Quality of life assessment before and after growth hormone treatment in adults with growth hormone deficiency. Acta Paediatr Scand Suppl 356: 70–72; discussion 73–74PubMedCrossRef

99.

Mesa J, Gómez JM, Hernández C et al. (2003) Growth hormone deficiency in adults: effects of replacement therapy on body composition and health-related quality of life. Med Clin (Barc) 120: 41–46

100.

Moshang T, Rundle AC, Graves DA et al. (1996) Brain tumor recurrence in children treated with growth hormone: the National Cooperative Growth Study experience. J Pediatr 128: S4–S7PubMedCrossRef

101.

Murray RD (2003) Adult growth hormone replacement: current understanding. Curr Opin Pharmacol 3: 642–649PubMedCrossRef

102.

Murray RD, Skillicorn CJ, Howell SJ et al. (1999) Influences on quality of life in GH deficient adults and their effect on response to treatment. Clin Endocrinol (Oxf) 51: 565–573

103.

Murray RD, Wieringa GE, Lissett CA et al. (2002) Low-dose GH replacement improves the adverse lipid profile associated with the adult GH deficiency syndrome. Clin Endocrinol (Oxf) 56: 525–532

104.

Nass R, Huber RM, Klauss V et al. (1995) Effect of growth hormone (hGH) replacement therapy on physical work capacity and cardiac and pulmonary function in patients with hGH deficiency acquired in adulthood. J Clin Endocrinol Metab 80: 552–557PubMedCrossRef

105.

Nolte W, Rädisch C, Armstrong VW et al. (1997) The effect of recombinant human GH replacement therapy on lipoprotein(a) and other lipid parameters in adults with acquired GH deficiency: results of a double-blind and placebo-controlled trial. Eur J Endocrinol 137: 459–466PubMedCrossRef

106.

O’Halloran DJ, Tsatsoulis A, Whitehouse RW et al. (1993) Increased bone density after recombinant human growth hormone (GH) therapy in adults with isolated GH deficiency. J Clin Endocrinol Metab 76: 1344–1348CrossRef

107.

O’Halloran DJ, Wieringa G, Tsatsoulis A, Shalet SM (1996) Increased serum lipoprotein(a) concentrations after growth hormone (GH) treatment in patients with isolated GH deficiency. Ann Clin Biochem 33: 330–334

108.

Page RC, Hammersley MS, Burke CW, Wass JA (1997) An account of the quality of life of patients after treatment for non-functioning pituitary tumours. Clin Endocrinol (Oxf) 46: 401–406

109.

Porretti S, Giavoli C, Ronchi C et al. (2002) Recombinant human GH replacement therapy and thyroid function in a large group of adult GH-deficient patients: when does L-T(4) therapy become mandatory? J Clin Endocrinol Metab 87: 2042–2045PubMedCrossRef

110.

Pouliot MC, Després JP, Lemieux S et al. (1994) Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am J Cardiol 73: 460–468PubMedCrossRef

111.

Raben MS (1962) Growth hormone. 2. Clinical use of human growth hormone. N Engl J Med 266: 82–86PubMed

112.

Rahim A, Holmes SJ, Adams JE, Shalet SM et al. (1998) Long-term change in the bone mineral density of adults with adult onset growth hormone (GH) deficiency in response to short or long-term GH replacement therapy. Clin Endocrinol (Oxf) 48: 463–469

113.

Rikken B, van Busschbach J, le Cessie S et al. (1995) Impaired social status of growth hormone deficient adults as compared to controls with short or normal stature. Dutch Growth Hormone Working Group. Clin Endocrinol (Oxf) 43: 205–211

114.

Rosen T, Bengtsson BA (1990) Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 336: 285–288PubMedCrossRef

115.

Rosén T, Bosaeus I, Tölli J et al. (1993) Increased body fat mass and decreased extracellular fluid volume in adults with growth hormone deficiency. Clin Endocrinol (Oxf) 38: 63–71

116.

Rosèn T, Edén S, Larson G et al. (1993) Cardiovascular risk factors in adult patients with growth hormone deficiency. Acta Endocrinol (Copenh) 129: 195–200

117.

Rosén T, Hansson T, Granhed H et al. (1993) Reduced bone mineral content in adult patients with growth hormone deficiency. Acta Endocrinol (Copenh) 129: 201–206

118.

Rosen T, Johannsson G, Bengtsson BA (1994) Consequences of growth hormone deficiency in adults, and effects of growth hormone replacement therapy. Acta Paediatr Suppl 399: 21–24PubMedCrossRef

119.

Rosén T, Wirén L, Wilhelmsen L et al. (1994) Decreased psychological well-being in adult patients with growth hormone deficiency. Clin Endocrinol (Oxf) 40: 111–116

120.

Rosenfalck AM, Fisker S, Hilsted J et al. (1999) The effect of the deterioration of insulin sensitivity on beta-cell function in growth-hormone-deficient adults following 4-month growth hormone replacement therapy. Growth Horm IGF Res 9: 96–105PubMedCrossRef

121.

Rosenfalck AM, Maghsoudi S, Fisker S et al. (2000) The effect of 30 months of low-dose replacement therapy with recombinant human growth hormone (rhGH) on insulin and C-peptide kinetics, insulin secretion, insulin sensitivity, glucose effectiveness, and body composition in GH-deficient adults. J Clin Endocrinol Metab 85: 4173–4181PubMedCrossRef

122.

Rosilio M, Blum WF, Edwards DJ et al. (2004) Long-term improvement of quality of life during growth hormone (GH) replacement therapy in adults with GH deficiency, as measured by questions on life satisfaction-hypopituitarism (QLS-H). J Clin Endocrinol Metab 89: 1684–1693PubMedCrossRef

123.

Russell-Jones DL, Bowes SB, Rees SE et al. (1998) Effect of growth hormone treatment on postprandial protein metabolism in growth hormone-deficient adults. Am J Physiol 274: E1050–E1056PubMed

124.

Russell-Jones DL, Watts GF, Weissberger A et al. (1994) The effect of growth hormone replacement on serum lipids, lipoproteins, apolipoproteins and cholesterol precursors in adult growth hormone deficient patients. Clin Endocrinol (Oxf) 41: 345–350

125.

Saggese G, Baroncelli GI, Bertelloni S et al. (1993) Effects of long-term treatment with growth hormone on bone and mineral metabolism in children with growth hormone deficiency. J Pediatr 122: 37–45PubMedCrossRef

126.

Salomon F, Cuneo RC, Hesp R, Sönksen PH (1989) The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N Engl J Med 321: 1797–1803PubMed

127.

Sartorio A, Molinari E, Riva G et al. (1995) Growth hormone treatment in adults with childhood onset growth hormone deficiency: effects on psychological capabilities. Horm Res 44: 6–11PubMed

128.

Serri O, Li L, Maingrette F et al. (2004) Enhanced lipoprotein lipase secretion and foam cell formation by macrophages of patients with growth hormone deficiency: possible contribution to increased risk of atherogenesis? J Clin Endocrinol Metab 89: 979–985PubMedCrossRef

129.

Sesmilo G, Biller BM, Llevadot J et al. (2000) Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency. A randomized, controlled clinical trial. Ann Intern Med 133: 111–122PubMed

130.

Snel YE, Brummer RJ, Doerga ME et al. (1995) Adipose tissue assessed by magnetic resonance imaging in growth hormone-deficient adults: the effect of growth hormone replacement and a comparison with control subjects. Am J Clin Nutr 61: 1290–1294PubMed

131.

Snel YE, Brummer RJ, Doerga ME et al. (1995) Energy and macronutrient intake in growth hormone-deficient adults: the effect of growth hormone replacement. Eur J Clin Nutr 49: 492–500PubMed

132.

Snel YE, Doerga ME, Brummer RM et al. (1995) Magnetic resonance imaging-assessed adipose tissue and serum lipid and insulin concentrations in growth hormone-deficient adults. Effect of growth hormone replacement. Arterioscler Thromb Vasc Biol 15: 1543–1548PubMed

133.

Snel YE, Doerga ME, Brummer RM et al. (1995) Resting metabolic rate, body composition and related hormonal parameters in growth hormone-deficient adults before and after growth hormone replacement therapy. Eur J Endocrinol 133: 445–450PubMedCrossRef

134.

Soares CN, Musolino NR, Cunha Neto M, et al. (1999) Impact of recombinant human growth hormone (RH-GH) treatment on psychiatric, neuropsychological and clinical profiles of GH deficient adults. A placebo-controlled trial. Arq Neuropsiquiatr 57(2A): 182–189PubMed

135.

Svensson J, Bengtsson BA, Rosén T et al. (2004) Malignant disease and cardiovascular morbidity in hypopituitary adults with or without growth hormone replacement therapy. J Clin Endocrinol Metab 89: 3306–3312PubMedCrossRef

136.

Svensson J, Fowelin J, Landin K et al. (2002) Effects of seven years of GH-replacement therapy on insulin sensitivity in GH-deficient adults. J Clin Endocrinol Metab 87: 2121–2127PubMedCrossRef

137.

Svensson J, Mattsson A, Rosén T et al. (2004) Three-years of growth hormone (GH) replacement therapy in GH-deficient adults: effects on quality of life, patient-reported outcomes and healthcare consumption. Growth Horm IGF Res 14: 207–215PubMedCrossRef

138.

Svensson J, Sunnerhagen KS, Johannsson G (2003) Five years of growth hormone replacement therapy in adults: age- and gender-related changes in isometric and isokinetic muscle strength. J Clin Endocrinol Metab 88: 2061–2069PubMedCrossRef

139.

Taback SP, Dean HJ (1996) Mortality in Canadian children with growth hormone (GH) deficiency receiving GH therapy 1967–1992. The Canadian Growth Hormone Advisory Committee. J Clin Endocrinol Metab 81: 1693–1696PubMedCrossRef

140.

Thorén M, Soop M, Degerblad M, Sääf M (1993) Preliminary study of the effects of growth hormone substitution therapy on bone mineral density and serum osteocalcin levels in adults with growth hormone deficiency. Acta Endocrinol (Copenh) (Suppl 2) 128: 41–43

141.

Toogood AA, Adams JE, O’Neill PA, Shalet SM (1997) Elderly patients with adult-onset growth hormone deficiency are not osteopenic. J Clin Endocrinol Metab 82: 1462–1466PubMedCrossRef

142.

Vahl N, Jørgensen JO, Hansen TB et al. (1998) The favourable effects of growth hormone (GH) substitution on hypercholesterolaemia in GH-deficient adults are not associated with concomitant reductions in adiposity. A 12 month placebo-controlled study. Int J Obes Relat Metab Disord 22: 529–536PubMedCrossRef

143.

Vandeweghe M, Taelman P, Kaufman JM (1993) Short and long-term effects of growth hormone treatment on bone turnover and bone mineral content in adult growth hormone-deficient males. Clin Endocrinol (Oxf) 39: 409–415

144.

Wallymahmed ME, Baker GA, Humphris G et al. (1996) The development, reliability and validity of a disease specific quality of life model for adults with growth hormone deficiency. Clin Endocrinol (Oxf) 44: 403–411

145.

Wallymahmed ME, Foy P, MacFarlane IA (1999) The quality of life of adults with growth hormone deficiency: comparison with diabetic patients and control subjects. Clin Endocrinol (Oxf) 51: 333–338

146.

Wallymahmed ME, Foy P, Shaw D et al. (1997) Quality of life, body composition and muscle strength in adult growth hormone deficiency: the influence of growth hormone replacement therapy for up to 3 years. Clin Endocrinol (Oxf) 47: 439–446

147.

Weaver JU, Monson JP, Noonan K et al. (1995) The effect of low dose recombinant human growth hormone replacement on regional fat distribution, insulin sensitivity, and cardiovascular risk factors in hypopituitary adults. J Clin Endocrinol Metab 80: 153–159PubMedCrossRef

148.

Webster JM, Stewart M, al-Maskari M, et al. (1997) The effect of growth hormone replacement therapy for up to 12 months on lipoprotein composition and lipoprotein(a) in growth hormone-deficient adults. Atherosclerosis 133: 115–121PubMedCrossRef

149.

Whitehead HM, Boreham C, McIlrath EM et al. (1992) Growth hormone treatment of adults with growth hormone deficiency: results of a 13-month placebo controlled cross-over study. Clin Endocrinol (Oxf) 36: 45–52

150.

Woodhouse LJ, Asa SL, Thomas SG, Ezzat S (1999) Measures of submaximal aerobic performance evaluate and predict functional response to growth hormone (GH) treatment in GH-deficient adults. J Clin Endocrinol Metab 84: 4570–4577PubMedCrossRef

151.

Wüster C, Abs R, Bengtsson BA et al. (2001) The influence of growth hormone deficiency, growth hormone replacement therapy, and other aspects of hypopituitarism on fracture rate and bone mineral density. J Bone Miner Res 16: 398–405PubMedCrossRef

Titel: Wachstumshormontherapie beim Erwachsenen
Versuch einer Bilanz nach einer Dekade
verfasst von: Dr. M. Faust
C.J. Strasburger
Publikationsdatum: 01.05.2008
Verlag: Springer-Verlag
Erschienen in: Die Innere Medizin / Ausgabe 5/2008
Print ISSN: 2731-7080
Elektronische ISSN: 2731-7099
DOI: https://doi.org/10.1007/s00108-008-2140-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Wachstumshormontherapie beim Erwachsenen

Versuch einer Bilanz nach einer Dekade

Zusammenfassung

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Update Innere Medizin

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2008

Die Therapie des Hypogonadismus des Mannes

Drohende Cumarinnekrose bei einer 24-jährigen Patientin mit stattgehabter Beinvenenthrombose

Diverse

Substitution mit Nebennierensteroiden

Thrombozytopenie bei einem Patienten nach perkutaner Koronarintervention

Kongresse des BDI 05/08

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Update Innere Medizin